Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free HBP Stock Alerts

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$2.04 0.00 (0.00%)
As of 05/4/2026 03:56 PM Eastern
Compare

HBP vs. FRX, PLI, ABCN, EMC, and TH

Should you be buying Helix BioPharma stock or one of its competitors? The main competitors of Helix BioPharma include Fennec Pharmaceuticals (FRX), ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), and Theratechnologies (TH). These companies are all part of the "biotechnology" industry.

How does Helix BioPharma compare to Fennec Pharmaceuticals?

Fennec Pharmaceuticals (TSE:FRX) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Fennec Pharmaceuticals has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$44.64M6.90-C$800.44K-C$0.34N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A

12.3% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Helix BioPharma has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -22.69%. Helix BioPharma's return on equity of -36.79% beat Fennec Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Fennec Pharmaceuticals-22.69% -236.42% 8.88%
Helix BioPharma N/A -36.79%-279.98%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Helix BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Helix BioPharma's average media sentiment score of 0.67 beat Fennec Pharmaceuticals' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Fennec Pharmaceuticals Neutral
Helix BioPharma Positive

Fennec Pharmaceuticals has a beta of 3.218074, suggesting that its stock price is 222% more volatile than the S&P 500. Comparatively, Helix BioPharma has a beta of 0.403644, suggesting that its stock price is 60% less volatile than the S&P 500.

Summary

Fennec Pharmaceuticals beats Helix BioPharma on 9 of the 13 factors compared between the two stocks.

How does Helix BioPharma compare to ProMetic Life Sciences?

ProMetic Life Sciences (TSE:PLI) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Helix BioPharma has lower revenue, but higher earnings than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Helix BioPharma's average media sentiment score of 0.67 beat ProMetic Life Sciences' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
ProMetic Life Sciences Neutral
Helix BioPharma Positive

ProMetic Life Sciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ProMetic Life SciencesN/A N/A N/A
Helix BioPharma N/A -36.79%-279.98%

Summary

Helix BioPharma beats ProMetic Life Sciences on 5 of the 9 factors compared between the two stocks.

How does Helix BioPharma compare to VIVO Cannabis?

Helix BioPharma (TSE:HBP) and VIVO Cannabis (CVE:ABCN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

In the previous week, Helix BioPharma's average media sentiment score of 0.67 beat VIVO Cannabis' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
VIVO Cannabis Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
VIVO CannabisN/AN/AN/AN/AN/A

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

VIVO Cannabis' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
VIVO Cannabis N/A N/A N/A

Summary

Helix BioPharma beats VIVO Cannabis on 3 of the 5 factors compared between the two stocks.

How does Helix BioPharma compare to Emblem?

Helix BioPharma (TSE:HBP) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Helix BioPharma's average media sentiment score of 0.67 beat Emblem's score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
Emblem Neutral

Emblem has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
Emblem$5.71M43.02-$24.81M-$0.19N/A

Emblem's return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
Emblem N/A N/A N/A

Summary

Emblem beats Helix BioPharma on 5 of the 9 factors compared between the two stocks.

How does Helix BioPharma compare to Theratechnologies?

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Helix BioPharma has a beta of 0.403644, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 0.256166, suggesting that its stock price is 74% less volatile than the S&P 500.

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.5% of Theratechnologies shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Comparatively, 1.2% of Theratechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Helix BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Theratechnologies
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Helix BioPharma's average media sentiment score of 0.67 beat Theratechnologies' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
Theratechnologies Neutral

Theratechnologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A

Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -19.83%. Theratechnologies' return on equity of 47.31% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
Theratechnologies -19.83%47.31%5.15%

Summary

Theratechnologies beats Helix BioPharma on 7 of the 12 factors compared between the two stocks.

Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HBP vs. The Competition

Export
MetricHelix BioPharmaBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$155.81MC$446.06MC$6.25BC$11.72B
Dividend Yield1.50%3.86%2.73%6.22%
P/E Ratio-34.004.1929.0423.83
Price / SalesN/A6,879.71476.4813.46
Price / Cash11.3213.1327.6282.69
Price / Book10.1477.749.674.48
Net Income-C$50.55M-C$96.07MC$3.55BC$300.68M
7 Day Performance0.99%0.71%1.70%0.12%
1 Month Performance20.00%3.87%5.62%2.88%
1 Year PerformanceN/A48.54%34.42%57.78%

Helix BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$2.04
flat		N/AN/AC$155.81MN/AN/A9
FRX
Fennec Pharmaceuticals
N/AC$9.40
+0.5%		N/AN/AC$324.07MC$44.64MN/A10
PLI
ProMetic Life Sciences
N/AN/AN/AN/AC$317.06MC$39.91MN/A487
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%		N/AN/AC$256.62MN/AN/AN/A
EMC
Emblem
N/A$1.88
+1.6%		N/AN/A$245.45M$5.71MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HBP) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel